Threshold
VC Fund
Menlo Park, United States
Threshold is a venture capital firm that invests in early-stage technology companies across sectors such as enterprise software, consumer platforms, fintech, and digital health. It provides capital to founders at seed and Series A stages and supports portfolio companies with strategic guidance, operational input, and access to industry networks. The firm collaborates with entrepreneurs on product development, market positioning, hiring, and go-to-market planning. Its investment approach centers on backing technology-driven businesses that address evolving market needs and scalable digital opportunities.
- Total investments:
- 545
- Last investment:
- Lead investor:
- 25%
- Fund size:
- $450M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Threshold invests in
Stages Threshold invests in
Countries Threshold invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 18 contacts → | |||
Round size
- Series A
- $2.5M–$24M
- Series B
- $5M–$65M
- Series C
- $5M–$75M
Investment Focus
Industry
- Software 92 (17%)
- Internet 45 (8%)
- Mobile 38 (7%)
- Information Technology 36 (7%)
- Artificial Intelligence 35 (6%)
Stage
- Series B 125 (23%)
- Series A 114 (21%)
- Series C 82 (15%)
- Series D 52 (10%)
- Funding Round 51 (9%)
Country
- United States 260 (48%)
- Canada 6 (1%)
- India 5 (1%)
- Israel 5 (1%)
- China 3 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Bill Bryant
General Partner
|
General Partner | Total investments: 25 | Find email | |
|
Maryanna Saenkohas
Senior Associate
|
Senior Associate | Total investments: 0 | Find email | |
Andreas Stavropoulos
Partner
|
Partner | Total investments: 46 | Find email | |
Arpit Mittal
Investor
|
Investor | Total investments: 2 | Find email | |
Carol Wentworth
Marketing partner
|
Marketing partner | Total investments: 0 | Find email | |
| See all 18 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Autopoiesis Sciences builds next-generation AI models designed to unlock transformative scientific breakthroughs across all critical research domains. The company's approach focuses on developing foundational reasoning capabilities that can autonomously drive discovery in areas where traditional AI has failed to deliver reliable results. | $11M / Seed / Sep 30, 2026 | ||
| Sequen is an AI-native Behavior Design Engine and reinforcement-learning-driven platform that powers adaptive in-session search. | $90M / Series B / Sep 10, 2026 | ||
| Ellis is an AI-native operations platform for private credit. | $10M / Seed / Jul 30, 2026 | ||
| Bluefish helps brands turn AI into a powerful new marketing channel to reach consumers and tell their story online. | $43M / Series B / Apr 14, 2026 | ||
| Sequen is an AI-native Behavior Design Engine and reinforcement-learning-driven platform that powers adaptive in-session search. | $16M / Series A / Mar 17, 2026 | ||
| Inertia is a commercial fusion energy company focused on laser-based fusion, grounded in proven physics, and aiming to deliver clean, limitless power. The company plans to innovate within the fusion sector, reinforcing its goal of commercializing fusion energy within the next decade. | $450M / Series A / Feb 11, 2026 | ||
| Veritus is a fintech start-up that builds an AI-native platform of intelligent agents for the consumer lending industry. | $10.1M / Seed / Feb 05, 2026 | ||
| Adaptation creates AI systems that adjust to changing real-world circumstances. | $50M / Seed / Feb 04, 2026 | ||
| Salvo is emerging as the leader in helping GI providers leap into a hybrid-care vision of the future of medicine, providing brick & mortar clinics with an easy to implement continuous care platform that saves time, increases revenue and improves patient outcomes.The company has announced agreements with 771 GI’s, representing 15% of allindependent GI’s in the US, to deploy wraparound care for their clinic patients. Included in its customers are five of the largest GI practices in the country, together seeing over 1.1 million GI patients a year. Salvo provides the tech and care delivery for modern, interdisciplinary care to treat chronic conditions that have surged in cost and prevalence: --IBS and IBD (over 40M affected) -- GERD and Celiac (over 50M affected) --MASH/MASLD, what was previously called “fatty liver disease” (over 80M) --Obesity (over 100M) The care benefits patients (76% of patients reported improved symptoms, five accepted medical conference abstracts on outcomes), generates incremental profit for practices (over $2M EBITDA improvement for a 100 GI practice), and reduces total healthcare costs (79% drop in GI-related ER utilization). | $8.5M / Series A / Jan 22, 2026 | ||
| Benepass is a benefits administration platform that helps companies manage and distribute employee perks and benefits. Through deep investments into the company's financial technology infrastructure, Benepass has made it easy for employers to offer global benefits that are personalized to every employee. The Benepass platform offers employeesfour different ways to spend their benefit dollars globally: card, mobile wallet, reimbursements, and a marketplace. | $40M / Series B / Jan 21, 2026 | ||
| See all 545 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Threshold invest in?
Threshold invests primarily in Software, Internet and Mobile startups, most often at Series B and Series A stage. Most of the 545 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Threshold invest in?
Threshold typically joins rounds of $2.5M–$24M at Series A, $5M–$65M at Series B and $5M–$75M at Series C. These are whole funding-round sizes, not Threshold's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Threshold took part in.
How do I contact Threshold?
Public channels for Threshold include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Threshold?
The team at Threshold includes Bill Bryant (General Partner), Maryanna Saenkohas (Senior Associate) and Andreas Stavropoulos (Partner), among 18 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
